Drug intelligence / Profile preview

ATX-GD-459

Development stage: Preclinical
Lead developer: Worgpharma
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

**ATX-GD-459** is an investigational, three-peptide antigen-specific immunotherapy developed by Apitope for Graves' disease. The product comprises thyrotropin receptor-derived antigen-processing independent epitopes, designed to restore immune tolerance to the thyrotropin receptor and reduce the pathogenic T-cell and stimulating autoantibody responses that drive Graves' hyperthyroidism. It was administered by intradermal injection in preclinical development and represented the three-peptide predecessor of the distinct two-peptide clinical formulation ATX-GD-59.

Targets

TSHR (Thyroid-stimulating hormone receptor)HLA-DR3

Beyond the preview

Go deeper on ATX-GD-459.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATX-GD-459.

Explore the full profile